Saturday, 6 March 2021

Man Dies One Week After Getting Paralysed From Sinopharm Covid-19 Vaccine


A 56-year-old man died on Thursday, exactly one week after he received the Covid-19 vaccine made by Chinese state-owned pharmaceutical company SinoPharm.

Jephter Gwandure a health officer who was based at Mutema Health Clinic in Gutu received the Sinopharm vaccine on 26 February 2021. He is reported to have adversely reacted to the vaccine. Just an hour after getting the Covid-19 vaccine, Gwandure fell ill and suffered a stroke which paralysed him. Gwandure was ultimately transferred to Parirenyatwa Hospital where he died on Thursday.

Narrating what had transpired the deceased’s daughter, Ivainashe Gwandure told the Masvingo Mirror,


“He was fine when he left home in the morning to take the vaccine. He was vaccinated at 12 pm and complained that he was feeling weak immediately afterwards. At 5 pm he suffered a stroke and collapsed.

“He was taken to Gutu Mission Hospital and later transferred to Masvingo General Hospital. He was transferred to Parirenyatwa Hospital where he died yesterday.”

Ivainashe also said that while medical experts are opining that the Covid-19 vaccine could have triggered high blood pressure, her father did not have a history of high blood pressure.


When reached for comment, the Provincial Medical Director for Masvingo Province, Dr Amadeus Shamu said that he was aware of the case but had not been updated on Gwandure’s death.


Man Dies One Week After Getting Paralysed From Sinopharm Covid-19 Vaccine
Man Dies One Week After Getting Paralysed From Sinopharm Covid-19 Vaccine


The Sinopharm vaccine which is made by a Chinese state-owned pharmaceutical company SinoPharm is an inactivated vaccine that works by using killed viral particles to expose the body’s immune system to the virus without risking a serious disease response.

This is different from the vaccines developed in the West which are mRNA vaccines. This means part of the coronavirus’ genetic code is injected into the body, triggering the body to begin making viral proteins, but not the whole virus, which is enough to train the immune system to attack.

According to the government, the Sinopharm vaccine has efficacy rates ranging from 76 to 86 per cent. Sinopharm announced on 30 December that phase three trials of the vaccine showed that it was 79.34% effective – lower than that of Pfizer and Moderna which are at 95%.

It should be noted that all vaccines come with recommendations and governments use these recommendations, available product information and guidelines issued by the World Health Organisation (WHO) to craft their own policies on people who should and should not take the vaccine.

The government of Zimbabwe recently launched an ambitious program to vaccine the country’s population and is currently vaccinating frontline workers.

No comments:

Post a Comment